×
Rezolute Common Stock Net 2013-2025 | RZLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Rezolute common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.
View More
Rezolute Common Stock Net 2013-2025 | RZLT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Rezolute common stock net from 2013 to 2025. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$245.4B
Amgen (AMGN)
$157.5B
Gilead Sciences (GILD)
$146.4B
Vertex Pharmaceuticals (VRTX)
$100B
Bristol Myers Squibb (BMY)
$98.1B
CSL (CSLLY)
$85.5B
GSK (GSK)
$79.6B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$59.9B
Argenex SE (ARGX)
$40.5B
BioNTech SE (BNTX)
$27.1B
Insmed (INSM)
$26.9B
Royalty Pharma (RPRX)
$20.9B
Biogen (BIIB)
$19.9B
Incyte (INCY)
$16.6B
Illumina (ILMN)
$15.5B
Genmab (GNMSF)
$15.3B
Genmab (GMAB)
$15B
Ascendis Pharma (ASND)
$11.9B
BioMarin Pharmaceutical (BMRN)
$11B
Moderna (MRNA)
$10.9B
QIAGEN (QGEN)
$10.8B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Exelixis (EXEL)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.5B
Bio-Techne Corp (TECH)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Halozyme Therapeutics (HALO)
$8.1B
Roivant Sciences (ROIV)
$8B